ROCKVILLE, Md., Nov. 22, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following November investor conferences:
Evercore ISI Biopharma Catalyst/Deep Dive Conference
Date: Wednesday, November 29, 2017
Location: Boston Harbor Hotel at Rowes Wharf
Fireside chat: Wednesday, November 29, 2017 at 2:20 p.m. ET
Barclays Gene Editing & Gene Therapy Summit
Date: Thursday, November 30, 2017
Location: Barclays offices, New York
Fireside chat: Thursday, November 30, 2017 at 9:20 a.m. ET
Panel: Gene Therapy – Gearing Up Towards Prime Time; Thursday, November 30, 2017 at 12:00 p.m. ET
A live webcast of the Evercore ISI fireside chat can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT:
Investors
Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com
Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com